Talaris Therapeutics : Costs Associated with Exit/Disposal - Form 8-K
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to... | April 14, 2023
Source: marketscreener.com
Scott Requadt News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Scott Requadt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Scott Requadt Today - Breaking & Trending Today
Cell Therapy Biotech Talaris Ends Two Kidney Transplant Trials, Restructures
While Talaris Therapeutics is ending two clinical tests of its cell therapy in kidney transplant patients, a third study in the autoimmune condition scleroderma is continuing. Meanwhile, the biotech’s restructuring plan is pursuing “strategic alternatives” that could include a merger or sale.
Source: medcitynews.com
Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial
20.10.2022 - BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) - Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ ... Seite 1
Source: wallstreet-online.de
Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update
15.08.2022 - All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained
Source: wallstreet-online.de